Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026

Silence Therapeutics (SLN) announced acceptance of SANRECO Phase 2 divesiran data for an oral presentation at the American Society of Hematology meeting.

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

clinical trial

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/04/2026 - 09:00 AM EST

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that data from its SANRECO Phase 2 study of divesiran, a first-in-class siRNA silencing TMPRSS6, in polycythemia vera (PV) was accepted for oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting being held December 12-15, 2026 in New Orleans, LA.

Presentation Details:

Presenting Author: Marina Kremyanskaya MD PhD (Icahn School of Medicine at Mount Sinai)

Title: Sanreco phase 2 randomized, double-blind trial of divesiran in patients with polycythemia vera

Publication Number: 928

Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Molecular Insights and New Approaches in MPNs
Session Date: December 14, 2026
Presentation Time: 3:30 PM-3:45 PM CT
Room: Ernest N. Morial Convention Center (MCCNO) - Hall B

About Silence Therapeutics

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. For more information, please visit https://www.silence-therapeutics.com/.